177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: Safety and efficacy

Journal of Nuclear Medicine

Volumn 57, Issue 7, 2016, Pages 1006-1013

  Baum, Richard P ^a   Kulkarni, Harshad R ^a   Schuchardt, Christiane ^a   Singh, Aviral ^a   Wirtz, Martina ^b   Wiessalla, Stefan ^a   Schottelius, Margret ^b   Mueller, Dirk ^a   Klette, Ingo ^a   Wester, Hans Jürgen ^b  

^a ZENTRALKLINIK BAD BERKA   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

PSMA; Radioligand therapy; Theranostics

Indexed keywords

ANTINEOPLASTIC AGENT; N,N' BIS [2 HYDROXY 5 (CARBOXYETHYL)BENZYL]ETHYLENEDIAMINE N,N DIACETIC ACID; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN LU 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (68GA)GLU-UREA-LYS(AHX)-HBED-CC; 177LU-PSMA-617; DIPEPTIDE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; ORGANOMETALLIC COMPOUND; SINGLE HETEROCYCLIC RINGS;

AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DISEASE COURSE; DOSIMETRY; DRUG ABSORPTION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE COUNT; FEASIBILITY STUDY; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HUMAN; IMAGE QUALITY; KARNOFSKY PERFORMANCE STATUS; KIDNEY FUNCTION; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OVERALL SURVIVAL; PAIN ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; THROMBOCYTOPENIA; TREATMENT RESPONSE; XEROSTOMIA; BLOOD; COHORT ANALYSIS; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; METASTASIS; PAIN; POSITRON EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOMETRY; TREATMENT OUTCOME;

AGED; ANTIGENS, SURFACE; COHORT STUDIES; DIPEPTIDES; DISEASE-FREE SURVIVAL; ERYTHROCYTE COUNT; GLUTAMATE CARBOXYPEPTIDASE II; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; LEUKOCYTE COUNT; MALE; NEOPLASM METASTASIS; ORGANOMETALLIC COMPOUNDS; PAIN; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOMETRY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84978426205     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.168443     Document Type: Article

References (34)

1. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011; 65:1180-1192.
2. Morris MJ, Molina A, Small EJ, et al. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol. 2015; 33:1356-1363.
3. Ramadan WH, Kabbara WK, Al Basiouni Al Masri HS. Enzalutamide for patients with metastatic castration-resistant prostate cancer. Onco Targets Ther. 2015; 8:871-876.
4. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369:213-223.
5. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363:411-422.
6. 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging. 2002; 1:96-101.
7. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010; 53:5333-5341.
8. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012; 23:688-697.
9. 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015; 56:668-674.
10. 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med. 2005; 46:850-858.
11. 131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014; 41:1280-1292.
12. 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015; 56:1169-1176.
13. Herrmann K, Bluemel C, Weineisen M, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015; 56:855-861.
14. Maurer T, Weirich G, Schottelius M, et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015; 68:530-534.
15. Baum RP, Kulkarni HR, Volkmer B, et al. Theranostics of metastatic prostate cancer applying Lu-177 PSMA small molecules in combination with Ga-68 PSMA PET/CT. Nuklearmediziner. 2015; 38:145-152.
16. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999; 35:1773-1782.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
18. Federal Institute for Drugs and Medical Devices. "Compassionate use" programs. http://www.bfarm.de/EN/Drugs/licensing/clinicalTrials/compUse/-node.html.2013. Accessed February 19, 2016.
19. Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013; 40:800-816.
20. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. U.S. Department of Health and Human Services website. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf. Published May 28, 2009. Accessed February 19, 2016.
21. 177Lu-DOTATOC. Recent Results Cancer Res. 2013; 194:519-536.
22. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005; 46:1023-1027.
23. 3]octreotate. Eur J Nucl Med Mol Imaging. 2009; 36:1138-1146.
24. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26:1148-1159.
25. Kulkarni H, Prasad V, Schuchardt C, Baum RP. Peptide receptor radionuclide therapy (PRRNT) of neuroendocrine tumors: relationship between tumor dose and molecular response as measured by somatostatin receptor PET/CT [abstract]. J Nucl Med. 2011; 52(SUPPL. 1):301P.
26. 177Lu octreotate? Clin Nucl Med. 2012; 37:e141-e147.
27. Baum RP, Kulkarni HR. THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy - the Bad Berka experience. Theranostics. 2012; 2:437-447.
28. Kulkarni HR, Baum RP. Theranostics with Ga-68 somatostatin receptor PET/CT: monitoring response to peptide receptor radionuclide therapy. PET Clin. 2014; 9: 91-97.
29. 68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015; 42:1794-1800.
30. Kinoshita Y, Kuratsukuri K, Landas S, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg. 2006; 30:628-636.
31. Kratochwil C, Giesel FL, Leotta K, et al. PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer. J Nucl Med. 2015; 56:293-298.
32. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991; 21:109-122.
33. 177Lu-DKFZ-617 PSMA of castrate-resistant meta-static prostate cancer: a two-centre study. EJNMMI Res. 2015; 5:114.
34. 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015; 42:1976-1983.